ArticleFrontiers in medicine2026

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes.

Qingna Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.